JP2005524399A5 - - Google Patents

Download PDF

Info

Publication number
JP2005524399A5
JP2005524399A5 JP2004501579A JP2004501579A JP2005524399A5 JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5 JP 2004501579 A JP2004501579 A JP 2004501579A JP 2004501579 A JP2004501579 A JP 2004501579A JP 2005524399 A5 JP2005524399 A5 JP 2005524399A5
Authority
JP
Japan
Prior art keywords
cancer cells
alcam
pharmaceutical composition
ability
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004501579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005524399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/014025 external-priority patent/WO2003093443A2/en
Publication of JP2005524399A publication Critical patent/JP2005524399A/ja
Publication of JP2005524399A5 publication Critical patent/JP2005524399A5/ja
Withdrawn legal-status Critical Current

Links

JP2004501579A 2002-05-03 2003-05-02 Alcamおよびalcam調節因子 Withdrawn JP2005524399A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37747902P 2002-05-03 2002-05-03
PCT/US2003/014025 WO2003093443A2 (en) 2002-05-03 2003-05-02 Alcam and alcam modulators

Publications (2)

Publication Number Publication Date
JP2005524399A JP2005524399A (ja) 2005-08-18
JP2005524399A5 true JP2005524399A5 (enExample) 2006-03-16

Family

ID=29401505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004501579A Withdrawn JP2005524399A (ja) 2002-05-03 2003-05-02 Alcamおよびalcam調節因子

Country Status (7)

Country Link
US (1) US20040048319A1 (enExample)
EP (1) EP1501544A4 (enExample)
JP (1) JP2005524399A (enExample)
CN (1) CN1662254A (enExample)
AU (1) AU2003225294A1 (enExample)
CA (1) CA2483912A1 (enExample)
WO (1) WO2003093443A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111623A1 (en) * 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
CA2596273C (en) * 2005-02-02 2017-11-14 Raven Biotechnologies, Inc. Adam-9 modulators
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
GB0705775D0 (en) * 2007-03-26 2007-05-02 Affitech As Product
WO2008133945A1 (en) * 2007-04-25 2008-11-06 The Trustees Of The University Of Pennsylvania Low level fluorescence detection at the light microscopic level
EP2065399A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH The present invention relates to methods for prediction of the therapeutic success of breast cancer therapy
WO2009059393A1 (en) * 2007-11-06 2009-05-14 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient sample
WO2009068423A2 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
SG168430A1 (en) * 2009-07-22 2011-02-28 Agency Science Tech & Res Molecular signature of human lung cancer initiating cells
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
KR101213445B1 (ko) 2011-01-13 2012-12-18 강원대학교산학협력단 백혈구의 혈관외유출 억제 활성 및 암세포의 전이 억제 활성을 갖는 펩타이드를 포함하는 약학 조성물
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
US10585102B2 (en) * 2012-10-11 2020-03-10 Vanderbilt University Characterization of cancer using detection of activated leukocyte cell adhesion molecule (ALCAM) shedding
EP3140426A4 (en) * 2014-05-07 2018-02-21 University of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
SG10202110908WA (en) 2015-05-04 2021-11-29 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2017015227A1 (en) * 2015-07-17 2017-01-26 The Trustees Of Columbia University In The City Of New York Methods of treating cd166-expressing cancer
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス,インコーポレーテッド Pd‐1及びctla‐4との免疫応答性を有する二重特異性並びにその使用方法
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス,インコーポレーテッド Cd137及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
SG11202000105QA (en) 2017-07-14 2020-02-27 Cytomx Therapeutics Inc Anti-cd166 antibodies and uses thereof
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス,インコーポレーテッド 二重特異性cd16結合分子、及び疾患の治療におけるその使用
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
WO2020072761A1 (en) * 2018-10-05 2020-04-09 The Regents Of The University Of Michigan Compositions and methods for treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5846535A (en) * 1990-10-12 1998-12-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0726912A4 (en) * 1993-11-02 2000-08-23 Univ Duke Cd6 ligand
US5998172A (en) * 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
US5968768A (en) * 1993-11-02 1999-10-19 Duke University CD6 ligand encoding sequence
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
CA2282410A1 (en) * 1997-03-03 1998-10-01 Bristol-Myers Squibb Company Monoclonal antibodies to human cd6
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
FR2796073B1 (fr) * 1999-07-07 2003-08-29 Centre Nat Rech Scient Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Similar Documents

Publication Publication Date Title
JP5109031B2 (ja) 細胞結合性ca125/o772pに結合する抗体およびその使用方法
CN113924103B (zh) 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
EP4017594A1 (en) Novel il-21 prodrugs and methods of use thereof
Dohlsten et al. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
JP2019107018A5 (enExample)
JP2008529497A5 (enExample)
JP2023547323A5 (enExample)
US9657066B2 (en) Pseudomonas exotoxin A with less immunogenic B cell epitopes
UA104130C2 (uk) Антитіло, що специфічно зв'язується з il-4 і іl-13 та спосіб лікування астми у ссавця за допомогою такого антитіла
JP2007504280A5 (enExample)
US7067131B2 (en) Methods for using anti-MUC18 antibodies
JP2010508847A5 (enExample)
IL184803A (en) Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer
JP2005505256A5 (enExample)
JP2006514024A5 (enExample)
WO2011137687A1 (zh) 一种抗癌胚抗原抗体及其应用
CN102027014A (zh) 用于治疗癌症的新抗体
EP4130046A1 (en) Platform for constructing multispecific antibody
CN111825766B (zh) 抗il-4r单域抗体及其应用
JP2024512858A (ja) 抗tslpナノ抗体およびその使用
JP2024503374A (ja) Cd147を標的とする抗体
WO2021197358A1 (zh) 一种抗pd-l1和pd-l2抗体及其衍生物和用途
Zhu et al. Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
CN117177999B (zh) 一种靶向IL-18Rβ的抗体及其应用
CN110139661A (zh) Igfb3及其受体相关疾病的治疗